# US 2023/0172986 A1 · Treatment and prevention of alloreactivity using virus-specific immune cells expressing chimeric antigen receptors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0172986 A1
- Document ID: US20230172986A1
- Status: Published application
- Kind: A1
- Application number: 17/997,171
- Filed: 2021-04-27
- Published: 2023-06-08
- Earliest claimed: 2020-04-27
- Assignees: Baylor College of Medicine
- Applicants: Baylor College of Medicine
- Inventors: David H. Quach; Cliona M. Rooney; Carlos A. Ramos
- Web page: https://patentgrep.com/patent/US20230172986A1

## CPC

- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/22: Immunosuppressive or immunotolerising
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/418: {Antigens related to induction of tolerance to non-self}
- A61K 40/4211: {CD19 or B4}
- A61K 40/4215: {Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30}
- A61K 40/46: Viral antigens
- A61P 31/22: for herpes viruses
- A61P 35/00: Antineoplastic agents
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70521: {CD28, CD152}
- C07K 14/70578: {NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 (NGF-receptor C07K14/71, TNF-receptor C07K14/7151)}
- C07K 16/2803: {against the immunoglobulin superfamily}
- C12N 5/0636: {T lymphocytes}
- H04B 1/713: using frequency hopping
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 40/50: characterised by the use of allogeneic cells
- A61K 2039/505: {comprising antibodies}
- A61K 2039/5156: {expressing foreign proteins}
- A61K 2239/29: Multispecific CARs
- A61K 2239/31: characterized by the route of administration
- A61K 2239/38: characterised by the dose, timing or administration schedule
- C07K 2317/53: Hinge
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2319/02: containing a signal sequence
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- H04B 2201/71338: Asynchronous systems
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- H04B: TRANSMISSION
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Treatment and prevention of diseases/conditions characterised by an alloreactive immune response using virus-specific immune cells, comprising a chimeric antigen receptor (CAR) or nucleic acid encoding a CAR, wherein the CAR comprises: (i) an antigen-binding domain which binds specifically to CD30, (ii) a transmembrane domain, and (iii) a signalling domain, wherein the signalling domain comprises: (a) an amino acid sequence derived from the intracellular domain of CD28, and (b) an amino acid sequence comprising an immunoreceptor tyrosine-based activation motif (ITAM), is disclosed.

## Claims

### Claim 1

A virus-specific immune cell comprising a chimeric antigen receptor (CAR) or nucleic acid encoding a CAR for use in a method of treating or preventing a disease or condition characterised by an alloreactive immune response, wherein the CAR comprises: (i) an antigen-binding domain which binds specifically to CD30, (ii) a transmembrane domain, and (iii) a signalling domain, wherein the signalling domain comprises: (a) an amino acid sequence derived from the intracellular domain of CD28, and (b) an amino acid sequence comprising an immunoreceptor tyrosine-based activation motif (ITAM).

### Claim 2

Use of a virus-specific immune cell comprising a chimeric antigen receptor (CAR) or nucleic acid encoding a CAR in the manufacture of a medicament for use in treating or preventing a disease or condition characterised by an alloreactive immune response, wherein the CAR comprises: (i) an antigen-binding domain which binds specifically to CD30, (i) a transmembrane domain, and (iii) a signalling domain, wherein the signalling domain comprises: (a) an amino acid sequence derived from the intracellular domain of CD28, and (b) an amino acid sequence comprising an immunoreceptor tyrosine-based activation motif (ITAM).

### Claim 3

A method of treating or preventing a disease or condition characterised by an alloreactive immune response, comprising administering to a subject a therapeutically or prophylactically effective quantity of virus-specific immune cells comprising a chimeric antigen receptor (CAR) or nucleic acid encoding a CAR, wherein the CAR comprises: (i) an antigen-binding domain which binds specifically to CD30, (ii) a transmembrane domain, and (iii) a signalling domain, wherein the signalling domain comprises: (a) an amino acid sequence derived from the intracellular domain of CD28, and (b) an amino acid sequence comprising an immunoreceptor tyrosine-based activation motif (ITAM).

### Claim 4 (depends on 1, 2, 3)

The virus-specific immune cell for use according to claim 1, the use according to claim 2, or the method according to claim 3, wherein the disease or condition characterised by an alloreactive immune response is a disease or condition associated with allotransplantation.

### Claim 5 (depends on 1, 2, 3, 4)

The virus-specific immune cell for use, the use, or the method according to any one of claims 1 to 4, wherein the disease or condition is graft versus host disease (GVHD).

### Claim 6 (depends on 1, 2, 3, 4)

The virus-specific immune cell for use, the use, or the method according to any one of claims 1 to 4, wherein the disease or condition is graft rejection.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The virus-specific immune cell for use, the use, or the method according to any one of claims 1 to 6, wherein the method comprises administering a therapeutically or prophylactically effective quantity of the virus-specific immune cells to a donor subject for an allotransplant prior to harvesting the allotransplant.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The virus-specific immune cell for use, the use, or the method according to any one of claims 1 to 7, wherein the method comprises administering a therapeutically or prophylactically effective quantity of the virus-specific immune cells to a recipient subject for an allotransplant.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The virus-specific immune cell for use, the use, or the method according to any one of claims 1 to 8, wherein the method comprises contacting an allotransplant with a therapeutically or prophylactically effective quantity of the virus-specific immune cells.

### Claim 10

A virus-specific immune cell comprising a chimeric antigen receptor (CAR) or nucleic acid encoding a CAR for use in a method of treating or preventing a disease or condition by allotransplantation, wherein the CAR comprises: (i) an antigen-binding domain which binds specifically to CD30, (ii) a transmembrane domain, and (iii) a signalling domain, wherein the signalling domain comprises: (a) an amino acid sequence derived from the intracellular domain of CD28, and (b) an amino acid sequence comprising an immunoreceptortyrosine-based activation motif (ITAM).

### Claim 11

Use of a virus-specific immune cell comprising a chimeric antigen receptor (CAR) or nucleic acid encoding a CAR in the manufacture of a medicament for use in treating or preventing a disease or condition by allotransplantation, wherein the CAR comprises: (i) an antigen-binding domain which binds specifically to CD30, (ii) a transmembrane domain, and (iii) a signalling domain, wherein the signalling domain comprises: (a) an amino acid sequence derived from the intracellular domain of CD28, and (b) an amino acid sequence comprising an immunoreceptor tyrosine-based activation motif (ITAM).

### Claim 12

A method of treating or preventing a disease or condition by allotransplantation, comprising administering to a subject a therapeutically or prophylactically effective quantity of virus-specific immune cells comprising a chimeric antigen receptor (CAR) or nucleic acid encoding a CAR, wherein the CAR comprises: (i) an antigen-binding domain which binds specifically to CD30, (ii) a transmembrane domain, and (ii) a signalling domain, wherein the signalling domain comprises: (a) an amino acid sequence derived from the intracellular domain of CD28, and (b) an amino acid sequence comprising an immunoreceptortyrosine-based activation motif (ITAM).

### Claim 13 (depends on 10, 11, 12)

The virus-specific immune cell for use according to claim 10, the use according to claim 11, or the method according to claim 12, wherein the method comprises administering a therapeutically or prophylactically effective quantity of the virus-specific immune cells to a donor subject for an allotransplant prior to harvesting the allotransplant.

### Claim 14 (depends on 10, 11, 12, 13)

The virus-specific immune cell for use, the use, or the method according to any one of claims 10 to 13, wherein the method comprises administering a therapeutically or prophylactically effective quantity of the virus-specific immune cells to a recipient subject for an allotransplant.

### Claim 15 (depends on 10, 11, 12, 13, 14)

The virus-specific immune cell for use, the use, or the method according to any one of claims 10 to 14, wherein the method comprises contacting an allotransplant with a therapeutically or prophylactically effective quantity of the virus-specific immune cells.

### Claim 16 (depends on 10, 11, 12, 13, 14, 15)

The virus-specific immune cell for use, the use, or the method according to any one of claims 10 to 15, wherein the allotransplantation comprises adoptive transfer of allogeneic immune cells.

### Claim 17 (depends on 10, 11, 12, 13, 14, 15, 16)

The virus-specific immune cell for use, the use, or the method according to any one of claims 10 to 16, wherein the disease or condition is a T cell dysfunctional disorder, a cancer or an infectious disease.

### Claim 18

A method of killing alloreactive immune cells, comprising contacting alloreactive immune cells with a virus-specific immune cell comprising a chimeric antigen receptor (CAR) or nucleic acid encoding a CAR for use in a method of treating or preventing a disease or condition characterised by an alloreactive immune response, wherein the CAR comprises: (i) an antigen-binding domain which binds specifically to CD30, (ii) a transmembrane domain, and (iii) a signalling domain, wherein the signalling domain comprises: (a) an amino acid sequence derived from the intracellular domain of CD28, and (b) an amino acid sequence comprising an immunoreceptor tyrosine-based activation motif (ITAM).

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The virus-specific immune cell for use, the use, or the method according to any one of claims 1 to 18, wherein the signalling domain comprises an amino acid sequence having at least 80% amino acid sequence identity to SEQ ID NO:26.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The virus-specific immune cell for use, the use, or the method according to any one of claims 1 to 19, wherein the transmembrane domain is derived from the transmembrane domain of CD28.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The virus-specific immune cell for use, the use, or the method according to any one of claims 1 to 20, wherein the transmembrane domain comprises an amino acid sequence having at least 80% amino acid sequence identity to SEQ ID NO:20.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The virus-specific immune cell for use, the use, or the method according to any one of claims 1 to 21, wherein the antigen-binding domain comprises an amino acid sequence having at least 80% amino acid sequence identity to SEQ ID NO:14, and an amino acid sequence having at least 80% amino acid sequence identity to SEQ ID NO:15.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The virus-specific immune cell for use, the use, or the method according to any one of claims 1 to 22, wherein the antigen-binding domain comprises an amino acid sequence having at least 80% amino acid sequence identity to SEQ ID NO:18.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The virus-specific immune cell for use, the use, or the method according to any one of claims 1 to 23, wherein the signalling domain comprises: (a) an amino acid sequence derived from the intracellular domain of CD3ζ.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The virus-specific immune cell for use, the use, or the method according to any one of claims 1 to 24, wherein the signalling domain comprises an amino acid sequence having at least 80% amino acid sequence identity to SEQ ID NO:25.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The virus-specific immune cell for use, the use, or the method according to any one of claims 1 to 25, wherein the CAR additionally comprises a hinge region provided between the antigen-binding domain and the transmembrane domain.

### Claim 27 (depends on 26)

The virus-specific immune cell for use, the use, or the method according to claim 26, wherein the hinge region comprises an amino acid sequence having at least 80% amino acid sequence identity to SEQ ID NO:33.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

The virus-specific immune cell for use, the use, or the method according to any one of claims 1 to 27, wherein the CAR comprises an amino acid sequence having at least 80% amino acid sequence identity to SEQ ID NO:35 or 36.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The virus-specific immune cell for use, the use, or the method according to any one of claims 1 to 28, wherein the virus-specific immune cell comprises a CAR comprising an antigen-binding domain which binds specifically to a target antigen other than CD30, or nucleic acid encoding a CAR comprising an antigen-binding domain which binds specifically to a target antigen other than CD30.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The virus-specific immune cell for use, the use, or the method according to any one of claims 1 to 29, wherein:
the CAR comprises: (i) an antigen-binding domain which binds specifically to CD30, (ii) a transmembrane domain, and (iii) a signalling domain comprising an immunoreceptor tyrosine-based activation motif (ITAM); and
wherein the virus-specific immune cell comprises a CAR comprising an antigen-binding domain which binds specifically to a target antigen other than CD30, or nucleic acid encoding a CAR comprising an antigen-binding domain which binds specifically to a target antigen other than CD30.

### Claim 31 (depends on 29, 30)

The virus-specific immune cell for use, the use, or the method according to claim 29 or claim 30, wherein the virus-specific immune cell comprises more than one non-identical CAR, or nucleic acid encoding more than one non-identical CAR.

### Claim 32 (depends on 29, 30, 31)

The virus-specific immune cell for use, the use, or the method according to any one of claims 29 to 31, wherein the target antigen other than CD30 is a cancer cell antigen.

### Claim 33 (depends on 29, 30, 31, 32)

The virus-specific immune cell for use, the use, or the method according to any one of claims 29 to 32, wherein the target antigen other than CD30 is selected from CD19, CD20, CD22, ROR1R, CD4, CD7, CD38, BCMA, Mesothelin, EGFR, GPC3, MUC1, HER2, GD2, CEA, EpCAM, LeY and PSCA.

### Claim 34 (depends on 29, 30, 31, 32, 33)

The virus-specific immune cell for use, the use, or the method according to any one of claims 29 to 33, wherein the target antigen other than CD30 is CD19.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

The virus-specific immune cell for use, the use, or the method according to any one of claims 1 to 34, wherein the virus-specific immune cell is a virus-specific T cell.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The virus-specific immune cell for use, the use, or the method according to any one of claims 1 to 35, wherein the virus-specific immune cell is specific for Epstein-Barr virus (EBV).
